Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Elenbecestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 24 Sep 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 01 Sep 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Apr 2013 Planned end date changed from 1 Oct 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.